Systems	O
Immunology	O
of	O
Diabetes	B:C0011847
-	O
Tuberculosis	O
Comorbidity	O
Reveals	O
Signatures	O
of	O
Disease	O
Complications	I:C0544688
.	O

Systems	O
Immunology	O
of	O
Diabetes	O
-	O
Tuberculosis	B:C0041296
Comorbidity	O
Reveals	O
Signatures	O
of	O
Disease	O
Complications	I:C0544688
.	O

Systems	O
Immunology	O
of	O
Diabetes	O
-	O
Tuberculosis	O
Comorbidity	O
Reveals	O
Signatures	O
of	O
Disease	B:C0544688
Complications	I:C0544688
.	O

Comorbid	O
diabetes	B:C0011849
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	B:C0011849
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	B:C0041296
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	B:C0041296
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	B:C1705586
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	B:C0011849
mellitus	I:C0011849
and	O
tuberculosis	O
remain	O
incompletely	O
understood	O
.	O

Comorbid	O
diabetes	O
mellitus	I:C0011849
(	O
diabetes	O
mellitus	I:C0011849
)	O
increases	O
tuberculosis	O
(	O
tuberculosis	O
)	O
risk	O
and	O
adverse	O
outcomes	I:C1705586
but	O
the	O
pathological	O
interactions	O
between	O
diabetes	O
mellitus	I:C0011849
and	O
tuberculosis	B:C0041296
remain	O
incompletely	O
understood	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	B:C0936012
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	B:C0370231
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	B:C0017262
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	B:C1609077
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	B:C1257890
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	B:C0041296
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	B:C0011849
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	B:C0241863
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	I:C0370231
gene	O
expression	I:C0017262
and	O
plasma	O
analytes	I:C1609077
,	O
comparing	O
South	O
Indian	I:C1257890
tuberculosis	O
patients	O
with	O
and	O
without	O
diabetes	O
mellitus	I:C0011849
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
tuberculosis	B:C0041296
.	O

Luminex	B:C0005507
assay	I:C0005507
of	O
plasma	O
cytokines	O
and	O
growth	O
factors	I:C0018284
delineated	O
a	O
distinct	O
biosignature	O
in	O
comorbid	O
TBDM	I:C1275743
in	O
this	O
cohort	O
.	O

Luminex	O
assay	I:C0005507
of	O
plasma	O
cytokines	O
and	O
growth	B:C0018284
factors	I:C0018284
delineated	O
a	O
distinct	O
biosignature	O
in	O
comorbid	O
TBDM	I:C1275743
in	O
this	O
cohort	O
.	O

Luminex	O
assay	I:C0005507
of	O
plasma	O
cytokines	O
and	O
growth	O
factors	I:C0018284
delineated	B:C0150312
a	O
distinct	O
biosignature	O
in	O
comorbid	O
TBDM	I:C1275743
in	O
this	O
cohort	O
.	O

Luminex	O
assay	I:C0005507
of	O
plasma	O
cytokines	O
and	O
growth	O
factors	I:C0018284
delineated	O
a	O
distinct	O
biosignature	O
in	O
comorbid	B:C1275743
TBDM	I:C1275743
in	O
this	O
cohort	O
.	O

Luminex	O
assay	I:C0005507
of	O
plasma	O
cytokines	O
and	O
growth	O
factors	I:C0018284
delineated	O
a	O
distinct	O
biosignature	O
in	O
comorbid	O
TBDM	I:C1275743
in	O
this	O
cohort	B:C0599755
.	O

Transcriptional	B:C1513400
profiling	I:C1513400
revealed	O
elements	O
in	O
common	O
with	O
published	O
tuberculosis	O
signatures	O
from	O
cohorts	O
that	O
excluded	O
diabetes	O
mellitus	I:C0011849
.	O

Transcriptional	O
profiling	I:C1513400
revealed	O
elements	O
in	O
common	O
with	O
published	B:C1704324
tuberculosis	O
signatures	O
from	O
cohorts	O
that	O
excluded	O
diabetes	O
mellitus	I:C0011849
.	O

Transcriptional	O
profiling	I:C1513400
revealed	O
elements	O
in	O
common	O
with	O
published	O
tuberculosis	B:C0041296
signatures	O
from	O
cohorts	O
that	O
excluded	O
diabetes	O
mellitus	I:C0011849
.	O

Transcriptional	O
profiling	I:C1513400
revealed	O
elements	O
in	O
common	O
with	O
published	O
tuberculosis	O
signatures	O
from	O
cohorts	B:C0599755
that	O
excluded	O
diabetes	O
mellitus	I:C0011849
.	O

Transcriptional	O
profiling	I:C1513400
revealed	O
elements	O
in	O
common	O
with	O
published	O
tuberculosis	O
signatures	O
from	O
cohorts	O
that	O
excluded	O
diabetes	B:C0011849
mellitus	I:C0011849
.	O

Neutrophil	B:C0200633
count	I:C0200633
correlated	O
with	O
the	O
molecular	O
degree	O
of	O
perturbation	O
,	O
especially	O
in	O
TBDM	O
patients	O
.	O

Body	B:C1305855
mass	I:C1305855
index	I:C1305855
and	O
HDL	O
cholesterol	I:C0023822
were	O
negatively	O
correlated	O
with	O
molecular	O
degree	O
of	O
perturbation	O
.	O

Body	O
mass	I:C1305855
index	I:C1305855
and	O
HDL	B:C0023822
cholesterol	I:C0023822
were	O
negatively	O
correlated	O
with	O
molecular	O
degree	O
of	O
perturbation	O
.	O

Body	O
mass	I:C1305855
index	I:C1305855
and	O
HDL	O
cholesterol	I:C0023822
were	O
negatively	B:C0205160
correlated	O
with	O
molecular	O
degree	O
of	O
perturbation	O
.	O

Diabetic	B:C0241863
complication	O
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	O
reprogramming	I:C1516924
were	O
activated	O
in	O
TBDM	O
above	O
levels	O
observed	O
with	O
diabetes	O
mellitus	I:C0011849
alone	O
.	O

Diabetic	O
complication	B:C0544688
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	O
reprogramming	I:C1516924
were	O
activated	O
in	O
TBDM	O
above	O
levels	O
observed	O
with	O
diabetes	O
mellitus	I:C0011849
alone	O
.	O

Diabetic	O
complication	O
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	B:C1516924
reprogramming	I:C1516924
were	O
activated	O
in	O
TBDM	O
above	O
levels	O
observed	O
with	O
diabetes	O
mellitus	I:C0011849
alone	O
.	O

Diabetic	O
complication	O
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	O
reprogramming	I:C1516924
were	O
activated	O
in	O
TBDM	B:C1275743
above	O
levels	O
observed	O
with	O
diabetes	O
mellitus	I:C0011849
alone	O
.	O

Diabetic	O
complication	O
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	O
reprogramming	I:C1516924
were	O
activated	O
in	O
TBDM	O
above	O
levels	O
observed	O
with	O
diabetes	B:C0011849
mellitus	I:C0011849
alone	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	B:C0008976
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	B:C1275743
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	B:C0599894
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	B:C0027950
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	B:C0021368
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	B:C0241863
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	B:C0544688
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	B:C1306577
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host	O
-	O
directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	B:C0009450
and	O
non-communicable	O
diseases	O
.	O

